1. Home
  2. Services
  3. Oncology Drug Screening

Oncology Drug Screening

Drugs for cancer treatment

Oncology drug screening applies high-throughput, multi-parameter experimental techniques to discover and identify potential anti-tumor compounds and biologics in oncology research. The process of drug screening in oncology serves as an essential component of developing new medications because it speeds up the identification of safe and innovative anti-cancer drugs while expanding treatment options.

Our Oncology Drug Screening Services

  1. Target Identification:
    The process of target identification involves locating essential molecular targets in tumor cells which drugs can successfully target. Drugs target essential proteins or genes which tumor cells depend upon for their growth and metastatic behavior among other processes. The identification of molecular targets serves as the essential starting point for creating oncology drugs and enables the production of targeted anti-cancer treatments. Learn More
  2. Drug Resistance Mechanism Analysis:
    Drug resistance in tumor cells typically results in unsuccessful treatments. The purpose of drug resistance mechanism analysis is to discover how tumor cells develop drug resistance through molecular mechanisms which helps develop new treatment strategies and overcome resistance. Learn More
  3. Biomarker Discovery:
    Biomolecules known as biomarkers demonstrate tumor presence development status and treatment reactions. Biomarker discovery targets the identification of biomarkers capable of predicting drug effectiveness while also providing prognosis assessment and guiding personalized treatment plans. Learn More
  4. Cell Signaling Pathway Mapping:
    Cell signaling pathways serve as critical networks that manage intracellular information transmission and regulation. The goal of cell signaling pathway mapping is to identify the main pathways present in tumor cells while analyzing how drugs affect these pathways alongside generating innovative concepts for developing new drugs. Learn More

Array Example

Panel / FocusExample Marker/Feature CombinationTarget ApplicationPossible Sample Preparation
A. Target Identification- Tumor-specific receptors: EGFR, HER2, c-Met, FGFRs
- Oncogenic kinases: BRAF (V600E), PI3K isoforms, JAK2
- Mutated tumor suppressors: p53 variants, RB1
- Surface markers: PD-L1, MUC1, EpCAM, etc.		1. Discover potential drug targets highly expressed or mutated in tumor cells
2. Compare tumor vs. normal tissues to find tumor-specific antigens
3. Prioritize targets for novel inhibitor or antibody development		- In vitro: Cell lysates from tumor lines vs. healthy lines; measure over/underexpression
- In vivo: Tumor tissue homogenates from animal models or patient biopsies, comparing normal vs. malignant tissues
B. Drug Resistance Mechanism Analysis- Efflux transporters: P-gp (ABCB1), MRP1/2 (ABCC1/2), BCRP (ABCG2)
- Bypass signaling: AXL, IGF-1R, FGFR, c-Met, etc.
- Apoptotic factors: Bcl-2, Bcl-xL, Mcl-1, Caspase-3 (cleaved)
- DNA repair: BRCA1, RAD51, PARP1, ATM/ATR		1. Identify how tumor cells develop or already harbor resistance (efflux, alternative RTKs, enhanced DNA repair)
2. Evaluate combination strategies (e.g., efflux inhibitors + main drug)
3. Correlate anti-apoptosis or other pathways with therapy failure		- In vitro: Compare parental vs. drug-resistant cell lines or subclones
- In vivo: Tumors post-therapy relapse; collect biopsies to see upregulation of efflux or bypass markers
C. Biomarker Discovery- Secreted or circulating markers: CA125, CEA, AFP, VEGF
- Exosomal proteins (e.g., tetraspanins, integrins, cargo proteins)
- Cytokines/chemokines relevant to tumor microenvironment (IL-6, TNF-α, MCP-1, etc.)		1. Uncover new soluble or exosomal markers in patient serum for early detection or treatment response
2. Stratify patients based on biomarker profiles predicting therapy outcome
3. Monitor disease progression or minimal residual disease via circulating biomarkers		- In vitro: Culture supernatants from tumor spheroids or conditioned media for secreted proteins/exosomes
- In vivo: Patient or animal serum/plasma, exosomes, or other biofluids (e.g., ascites) for biomarker screening; also tumor lysates if analyzing local marker expression
D. Cell Signaling Pathway Mapping- Key pathways: MAPK (ERK, p38, JNK), PI3K/Akt/mTOR, JAK/STAT, NF-κB, Wnt/β-catenin
- Phospho- vs. total proteins for each node (p-ERK vs. ERK, p-Akt vs. Akt, etc.)
- Receptor tyrosine kinases (EGFR, HER2, c-Met) and downstream effectors		1. Determine which pathways drive cell proliferation or survival in a given tumor
2. Assess on-target inhibition by a compound (e.g., reduce p-ERK levels) or potential off-target activation of other pathways
3. Design combination therapies blocking multiple or alternative routes		- In vitro: Cell lysates from dose-response/time-course experiments with inhibitors
- In vivo: Tumor tissue post-treatment, analyzed for changes in p-Akt, p-ERK, etc. to confirm pathway blockade or bypass signaling

Our Near-Infrared Microarray Protein Chip Technology Platform

Based on independent innovation, Creative Diagnostics combines advanced technologies such as laser confocal microscopy, near-infrared fluorescence labeling, and special functional silicone membranes with protein chips to establish a unique high-throughput protein chip detection platform. This platform has significant advantages such as high throughput, multi-index joint detection, and high cost performance, and can provide comprehensive and accurate oncology drug screening services for the majority of scientific research users.

Features of Our Detection Platform:

  • High Throughput and Automation: The combination of special functional silicone membranes with near-infrared fluorescence labeling technology enables both high-throughput detection capabilities and automated system operation.
  • High Sensitivity and Broad Spectrum: The special functional silicone membranes demonstrate exceptional sensitivity and tolerance while covering a broad spectrum and exhibiting strong biocompatibility.
  • Precise Detection: The laser confocal system delivers high sensitivity together with a wide measurement linear range and superior image resolution without any distortion.

Service Highlights

  • Customized Services: We offer experimental design and data analysis services that are customized to fit your particular requirements.
  • Professional Technical Team: Our professional technical team provides experienced support and consulting services.
  • Strict Quality Control: Our strict quality control standards function to guarantee both accurate and reliable experimental results.

Service Cycle and Process

  1. Project Consultation: Customers communicate with our technical team to clarify experimental objectives and specific needs.
  2. Experimental Design: Our technical team develops a detailed experimental plan based on customer needs.
  3. Sample Preparation: Customers provide qualified samples or entrust us with sample preparation.
  4. Experimental Operation: Our technicians perform experimental operations according to the experimental plan.
  5. Data Analysis: We conduct professional analysis of experimental data and provide detailed analysis reports.
  6. Results Delivery: We deliver experimental results and analysis reports to customers.

Through our cutting-edge technology platform along with our full service suite and expert team we enable oncology drug development and speed up new drug discovery to collaboratively fight cancer. We eagerly anticipate working together to make a positive impact on human health.

Online Inquiry
Services